Orfadin

Orfadin

a trademark for nitisinone.
References in periodicals archive ?
M2 EQUITYBITES-September 6, 2017-Sobi announces approval receipt from US FDA for reduces dosing frequency of Orfadin
M2 PHARMA-September 6, 2017-Sobi announces approval receipt from US FDA for reduces dosing frequency of Orfadin
The US Food and Drug Administration (FDA) has as of 22 April 2016, approved Orfadin (nitisinone) Oral Suspension for the treatment of hereditary tyrosinaemia type-1 (HT-1) in combination with dietary restriction of tyrosine and phenylanine.
This drug is Nitisinone (NTBC) whose chemical name is 2- (2-nitro-4-trifluoromethylbenzoyl) 1, 3--cyclohexanedione and is sold under the brand name Orfadin.
11 January 2011 - Biotech company Swedish Orphan Biovitrum AB (STO: BVT) said today that South Korean pharmaceutical company BL&H Co, Ltd will distribute its rare diseases drugs Orfadin and Kepivance in the country.
Nashville, TN has received approval from the FDA to market nitisinone capsules under the name of Orfadin to treat hereditary tyrosinemia type 1 (HT-1), a rare pediatric disease causing progressive liver failure and liver cancer in young children.
The company said Raffensperger has led the commercial organisation responsible for launching Sobi's haemophilia products in Europe, as well as the expansion of Sobi's global brands Orfadin and Kineret in Europe and North America.
M2 PHARMA-May 19, 2017-Sobi's Orfadin capsules approved in Saudi Arabia
Continuous supply of medicine Orfadin, according to the client~s needs and according to detailed specification in the tender documents.
Also, sales of Kineret increased by 12% in CER and by 1% in SEK, while sales of Orfadin increased by 21% in CER and by 9% in SEK.
M2 EQUITYBITES-May 19, 2017-Sobi's Orfadin capsules approved in Saudi Arabia
M2 PHARMA-May 17, 2017-Swedish Orphan Biovitrum AB announces Orfadin capsule approval in Saudi Arabia to treat hereditary tyrosinemia type 1